Jae H Park

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
    Jae H Park
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Discov Med 9:277-88. 2010
  2. ncbi Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Jae H Park
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Expert Rev Hematol 4:427-36. 2011
  3. ncbi Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
  4. ncbi ATRA plus arsenic gets another "A" in APL
    Jae H Park
    Memorial Sloan Kettering Cancer Center, USA
    Blood 120:1535-6. 2012
  5. ncbi Curing all patients with acute promyelocytic leukemia: are we there yet?
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, 525 East 68th Street, Box 130, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1215-33, viii. 2011
  6. ncbi Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011
  7. ncbi Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy
    Jae H Park
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    Oncology (Williston Park) 25:733-41. 2011
  8. ncbi Cellular therapies in acute lymphoblastic leukemia
    Jae H Park
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 569, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1281-301. 2011

Collaborators

  • Martin S Tallman
  • Dan Douer
  • Michel Sadelain
  • Glenn Heller
  • Katherine S Panageas
  • Maria J Schymura
  • Muhamed Baljevic
  • Renier J Brentjens
  • Mark Frattini
  • Malgorzata Olszewska
  • David Scheinberg
  • Daniel Hollyman
  • Domenick Pirraglia
  • Jessica K Altman
  • James Hosey
  • MARCO L DAVILA
  • Clare Taylor
  • Yvette Bernal
  • Peter Maslak
  • Xiuyan Wang
  • Hollie Pegram
  • Raymond Yeh
  • Elmer Santos
  • Elizabeth Halton
  • Yelena Usachenko
  • Isabelle Riviere
  • Mark Heaney
  • Mark Przybylowski
  • Joseph Jurcic
  • Oriana Borquez-Ojeda
  • Eytan Stein
  • Shirley Bartido
  • Jolanta Stefanski

Detail Information

Publications8

  1. ncbi Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
    Jae H Park
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Discov Med 9:277-88. 2010
    ....
  2. ncbi Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Jae H Park
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Expert Rev Hematol 4:427-36. 2011
    ..Cure rates of APL can be further increased by implementing management strategies to reduce early hemorrhagic deaths, which remain the major cause of treatment failure with the current therapy...
  3. ncbi Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
    ..These data highlight a need to educate health care providers across a wide range of medical fields, who may be the first to evaluate patients with APL, to have a major effect on early death and the cure rate of APL...
  4. ncbi ATRA plus arsenic gets another "A" in APL
    Jae H Park
    Memorial Sloan Kettering Cancer Center, USA
    Blood 120:1535-6. 2012
    ....
  5. ncbi Curing all patients with acute promyelocytic leukemia: are we there yet?
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, 525 East 68th Street, Box 130, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1215-33, viii. 2011
    ....
  6. ncbi Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011
    ..These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol)...
  7. ncbi Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy
    Jae H Park
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    Oncology (Williston Park) 25:733-41. 2011
    ..Cure rates of APL may be further increased by adopting management strategies to reduce early hemorrhagic deaths, which now appear to be the major cause of treatment failure...
  8. ncbi Cellular therapies in acute lymphoblastic leukemia
    Jae H Park
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 569, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1281-301. 2011
    ....